Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

Gliomas are the most common primary brain tumors with heterogeneous morphology and variable prognosis. Treatment decisions in patients rely mainly on histologic classification and clinical parameters. However, differences between histologic subclasses and grades are subtle, and classifying gliomas is subject to a large interobserver variability. To improve current classification standards, we have performed gene expression profiling on a large cohort of glioma samples of all histologic subtypes and grades. We identified seven distinct molecular subgroups that correlate with survival. These include two favorable prognostic subgroups (median survival, >4.7 years), two with intermediate prognosis (median survival, 1-4 years), two with poor prognosis (median survival, <1 year), and one control group. The intrinsic molecular subtypes of glioma are different from histologic subgroups and correlate better to patient survival. The prognostic value of molecular subgroups was validated on five independent sample cohorts (The Cancer Genome Atlas, Repository for Molecular Brain Neoplasia Data, GSE12907, GSE4271, and Li and colleagues). The power of intrinsic subtyping is shown by its ability to identify a subset of prognostically favorable tumors within an external data set that contains only histologically confirmed glioblastomas (GBM). Specific genetic changes (epidermal growth factor receptor amplification, IDH1 mutation, and 1p/19q loss of heterozygosity) segregate in distinct molecular subgroups. We identified a subgroup with molecular features associated with secondary GBM, suggesting that different genetic changes drive gene expression profiles. Finally, we assessed response to treatment in molecular subgroups. Our data provide compelling evidence that expression profiling is a more accurate and objective method to classify gliomas than histologic classification. Molecular classification therefore may aid diagnosis and can guide clinical decision making.

[1]  Thomas Ragg,et al.  The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.

[2]  M. J. van den Bent,et al.  Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. , 2007, Cancer research.

[3]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[5]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[6]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[7]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[8]  Mark J. van der Laan,et al.  A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap , 2003 .

[9]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[10]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[11]  Amy V Kapp,et al.  Are clusters found in one dataset present in another dataset? , 2007, Biostatistics.

[12]  K. Wong,et al.  Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. , 2005, Cancer research.

[13]  Tom C. Freeman,et al.  Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data , 2008, Molecular Cancer Therapeutics.

[14]  J. Acebes,et al.  Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas , 2003, Cancer.

[15]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[17]  Jocelyn A Andrel,et al.  Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. , 2007, International journal of radiation oncology, biology, physics.

[18]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[19]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[20]  Jord H A Nagel,et al.  Gene expression profiles associated with treatment response in oligodendrogliomas. , 2005, Cancer research.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Schutte,et al.  Allelotype of 28 human breast cancer cell lines and xenografts , 2003, British Journal of Cancer.

[23]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[24]  Koji Yoshimoto,et al.  Primary Glioblastomas Express Mesenchymal Stem-Like Properties , 2006, Molecular Cancer Research.

[25]  Yuri Kotliarov,et al.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. , 2009, Cancer research.

[26]  S. Horvath,et al.  Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age , 2008, BMC Medical Genomics.

[27]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[28]  Helena F. Deus,et al.  Exploratory Analysis of the Copy Number Alterations in Glioblastoma Multiforme , 2008, PloS one.

[29]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Caterina Giannini,et al.  Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome , 2007, Journal of neuropathology and experimental neurology.

[32]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[33]  N. Hashimoto,et al.  Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis , 2007, Clinical Cancer Research.

[34]  S. Ishii,et al.  Using gene expression profiling to identify a prognostic molecular spectrum in gliomas , 2008, Cancer science.

[35]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[36]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.